Obicetrapib

Studies of obicetrapib in people

11 studies gave obicetrapib to people and measured what changed

What changedDesignPeopleSource

no change: Has no effect on HbA1cLSMD -0.02%, 95% CI -0.04 to 0.00

down: Lowers the risk of new-onset diabetes6.4% versus 8.5%; adjusted OR 0.69, 95% CI 0.47-1.03

Review of trials52 weeks1,700 people pooledBothEuropean journal of preventive cardiology, Oct 24, 2026

up: Increases HDL-fraction lipophilic antioxidants

down: Decreases oxidized LDL

up: Increases HDL2 cholesterol

Trial8 weeks12 peopleJapanese participants; n = 12 per groupScientific reports, Oct 16, 2026

down: Decreases LDL-CMD -37.45

down: Decreases non-HDL-CMD -32.04

down: Decreases Apolipoprotein BMD -24.71

Review of trials3,512 people pooledPatient cohortsCardiology in review, Jun 29, 2026

down: Decreases estimated glomerular filtration rate reduction6.7 % vs. 8.7 % RR 0.77 [0.59, 1.00]

no change: Has no effect on blood pressure

no change: Has no effect on mortality

Review of trials365 days2,880 people pooledBothmean age 64 yearsOlder adults; HeFH or ASCVDAmerican journal of preventive cardiology, Mar 24, 2026

down: Decreases LDL cholesterol-36.3% placebo-adjusted change; 95% CI -42.2% to -30.4%

Randomized trial84 days354 peopleBothHeterozygous familial hypercholesterolemia on maximally tolerated lipid-lowering therapyNature medicine, Feb 27, 2026

down: Decreases LDL cholesterol-33.17% (95% CI, -36.21 to -30.13)

down: Decreases non-HDL cholesterol-16.1% (95% CI, -19.1 to -13.1)

Review of trials6,025 people pooledOn top of statin therapyJournal of clinical lipidology, Feb 26, 2026

down: Decreases oxidized LDL

up: Increases lipophilic antioxidants

up: Increases carotenoids

Randomized trial8 weeks12 peopleIn Japanese participantsResearch Square, Jan 12, 2026

down: Decreases LDL-C-33%

up: Increases HDL-C+125%

down: Decreases p-Tau2171.1% obicetrapib vs. 4.8% with placebo

Randomized trial12 months1,727 peopleBothmean 65 yearsOlder adults; atherosclerosis cardiovascular diseaseAAIC 2025 abstract, Dec 23, 2025

down: Decreases LDL cholesterolMD -27.29 mg/dL; 95% CI -33.65 to -20.93

up: Increases HDL cholesterolMD 70.96 mg/dL; 95% CI 64.71 to 77.20

up: Increases achievement of LDL-C target <55 mg/dLRR 6.42; 95% CI 5.15 to 8.01

Review of trials3,386 people pooledStatin-treated adultsAHA Scientific Sessions 2025 abstract, Nov 3, 2025

down: Decreases total LDL particle number-32.62% vs +7.51% with placebo; between-group difference -40.13% (95% CI -43.33 to -36.93)

down: Decreases small LDL particle number-68.02% vs +32.58% with placebo; between-group difference -100.61% (95% CI -110.65 to -90.57)

Randomized trial2,024 peopleAlongside maximally tolerated lipid-lowering therapyAHA Scientific Sessions 2025 abstract, Nov 3, 2025

down: Decreases p-Tau217Adjusted mean increases 2.09% versus 4.94% with placebo

Randomized trial12 months1,535 peopleBothMedian age was 67 yearsOlder adults; ASCVDThe journal of prevention of Alzheimer's disease, Oct 17, 2025